Antiviral Drugs in the Immunocompetent Host: Part II. Treatment of Influenza and Respiratory Syncytial Virus Infections - February 15, 2003

February 15, 2003 Table of Contents

Antiviral Drugs in the Immunocompetent Host: Part II. Treatment of Influenza and Respiratory Syncytial Virus Infections

RICHARD COLGAN, M.D., University of Maryland School of Medicine, Baltimore, Maryland

ROBERT MICHOCKI, Pharm.D., B.C.P.S., University of Maryland School of Pharmacy, Baltimore, Maryland

LISA GREISMAN, M.D., University of Maryland Medical Center, Baltimore, Maryland

TRACY A. WOLFF MOORE, M.D., University of Maryland School of Medicine, Baltimore, Maryland

Am Fam Physician.�2003�Feb�15;67(4):763-766.

� This is part II of a two-part article on antiviral drugs. Part I, “Treatment of Hepatitis, Cytomegalovirus, and Herpes Infections,” appears in this issue on page 757.

Family physicians should be familiar with the various drugs available for treating and preventing viral infections. Part II of this two-part article focuses on agents used to manage influenza and respiratory syncytial virus. Rimantadine and amantadine traditionally have been used to prevent and treat influenza type A infections. The neuraminidase inhibitors zanamivir and oseltamivir have a broadened spectrum of activity in the treatment and prevention of influenza types A and B. Ribavirin has been used in some high-risk infants to treat respiratory syncytial virus infections, and palivizumab can be used for prophylaxis.

RNA viruses generally are benign in the early stage of infection, but they have the potential to induce acute respiratory distress syndrome if they spread to the lower respiratory tract or progress to pneumonia. Antiviral drugs can be used to treat and prevent these infections, although they are not a substitute for vaccine. Part II of this article focuses on antiviral agents used in the management of influenza and respiratory syncytial virus (RSV).

Influenza Viruses

Antiviral drugs that prevent and treat influenza should be considered adjuncts to vaccine—not substitutes. Traditionally, amantadine (Symmetrel) and, to a lesser extent, rimantadine (Flumadine) have been used for preventing and treating influenza type A (Table 1).1–4� However, in 1999, two drugs that effectively treat and prevent influenza types A and B were introduced. These drugs, zanamivir (Relenza) and oseltamivir (Tamiflu), provide more complete coverage when the type of influenza is unknown (Table 2).1–4

TABLE 1
Comparison of Amantadine and Rimantadine

Drug factors	Amantadine (Symmetrel)			Rimantadine (Flumadine)
Generic availability	Yes			Yes
Dosage forms	Liquid and tablet			Liquid and tablet
Treatment and prevention of influenza type A in adults	Yes			Yes
Treatment of influenza type A in children	Yes			Not approved
Prevention of influenza type A in children	Yes			Yes
Dosages for treatment of influenza type A	Adults* and children 12 years of age: 200 mg daily until 24 to 48 hours after symptoms have disappeared			Adults* and children 10 years of age: 100 mg twice daily for seven days
			or	Not approved for children < 10 years of age
		100 mg twice daily† until 24 to 48 hours after symptoms have disappeared
	Children one to nine years of age: 5 mg per kg daily (up to 150 mg daily) until 24 to 48 hours after symptoms have disappeared
	Children 10 to 11 years of age: 100 mg twice daily until 24 to 48 hours after symptoms have disappeared
Dosages for prevention of influenza A‡	Adults* and children 12 years of age: 200 mg daily for at least seven days			Adults* and children 10 years of age: 100 mg twice daily for at least seven days
			or
		100 mg twice daily for at least seven days		Children < 10 years of age: 5 mg per kg daily (up to 150 mg daily) for at least seven days
	Children one to nine years of age: 5 mg per kg daily (up to 150 mg daily) for at least seven days
	Children 10 to 11 years of age: 100 mg twice daily for at least seven days
Prevention and treatment of influenza B	No			No
Dosage reduction in renal impairment	Yes (creatinine clearance 50 mL per minute [0.83 mL per second])			Yes (creatinine clearance 10 mL per min [0.17 mL per second])
Side effects	CNS and GI			Primarily GI
Cost (generic)�
Five-day treatment (adult dosage)	$18 ($4 to $5)			$29 ($26)
42-day treatment (adult dosage in community outbreaks)	$106 ($28 to $31)			$171 ($154)

CNS = central nervous system; GI = gastrointestinal.

*—Dosage for adults up to age 64. Dosage for adults age 65 and older is 100 mg daily.

†—If CNS effects develop with the once-a-day dosage, the split dosage might reduce side effects.

‡—All dosages may be used for up to 42 days during community outbreaks.

�—Estimated cost to the pharmacist based on average wholesale prices in Red book. Montvale, N.J.: Medical Economics Data, 2002. Cost to the patient will be higher, depending on prescription filling fee.

Information from references 1 through 4.

TABLE 2
Comparison of Oseltamivir and Zanamivir

Drug factors		Oseltamivir (Tamiflu)		Zanamivir (Relenza)
Generic availability		No		No
Dosage forms		Liquid and capsule		Powder for oral inhalation
Treatment of influenza types A and B in adults		Yes		Yes
Treatment of influenza types A and B in children		Yes, in children > one year of age		Yes, in children seven years of age
Prevention of influenza types A and B in adults		Yes		FDA approval pending
Prevention of influenza types A and B in children		Yes, in children 13 years of age		FDA approval pending
Dosage for treatment of influenza types A and B*		Adults and children 13 years: 75 mg twice daily for five days		Two inhalations (10 mg) twice daily for five days
		Children one to 12 years (following doses are given twice daily for five days):
			15 kg (33 lb) or less: 30 mg
			15 kg to 23 kg (51 lb): 45 mg
			23 kg to 40 kg (88 lb): 60 mg
			> 40 kg: 75 mg
Dosage for prevention of influenza types A and B		Adults and children 13 years: 75 mg once daily for at least seven days†		Approval pending. Two inhalations (10 mg) once daily for at least seven days†
Dosage reduction in renal impairment		Yes (creatinine clearance 30 mL per minute [0.5 mL per second])		No
Side effects		GI		Minimal
Cost‡
	Five-day treatment (adult dosage)	$63		$50
	42-day treatment (adult dosage in community outbreaks)	$265		$212 (approval pending)
Precautions		Take with food to improve tolerance		Not recommended in patients with asthma or COPD
		Suspension should be shaken before each use and is stable at room temperature for 10 days
				May cause bronchospasm

FDA = U.S. Food and Drug Administration; GI = gastrointestinal; COPD = chronic obstructive pulmonary disease.

*—Begin treatment within 48 hours of onset of symptoms. If using zanamivir, two doses should be taken on the first day of dosing, provided there are at least two hours between doses. Subsequent doses should be spaced approximately 12 hours apart.

†—May be used for up to 42 days during community outbreaks.

‡—Estimated cost to the pharmacist based on average wholesale prices in Red book. Montvale, N.J.: Medical Economics Data, 2002. Cost to the patient will be higher, depending on prescription filling fee.

Information from references 1 through 4.

INFLUENZA TYPE A

Amantadine and Rimantadine

Amantadine was the first drug approved for prophylaxis of influenza type A (in 1966), and in 1976, it was approved for treatment and prophylaxis in adults and children older than one year. Rimantadine became available in 1993 for treatment and prophylaxis of influenza type A in adults and for prophylaxis in children. Neither of these drugs is effective against influenza type B.

Treatment usually is continued for three to five days or discontinued 24 to 48 hours following resolution of symptoms. The efficacy of both drugs is similar, and the average duration of illness is shortened by approximately one day.5

These drugs can be used for prophylaxis in high-risk patients (Table 3)6 and for influenza-related complications if an outbreak of influenza occurs within two weeks following vaccination.4 In a recent review, the average effectiveness of amantadine and rimantadine for the prevention of influenza was 61 and 72 percent, respectively.7

TABLE 3
Using Antiviral Drugs for Influenza

Prophylaxis
Unvaccinated patients at high risk
Patients at high risk who were vaccinated at the onset of the epidemic (two weeks for patients age nine and older; six weeks for patients age eight or younger)
Vaccinated patients at high risk, when vaccine virus and epidemic virus are a poor antigenic match
Patients with immunodeficiency
Unvaccinated patients caring for persons at high risk and patients living in households with persons at high risk
All residents and staff members in long-term care institutions where there are patients at high risk during an institutional outbreak (for at least 14 days)
Consider for persons in the patient's household who are exposed
Treatment
All patients at high risk who develop influenza
Patients with severe influenza
Consider for use in patients with influenza who wish to shorten the duration of illness

Reprinted with permission from Couch RB. Prevention and treatment of influenza. N Engl J Med 2000;343:1784.

Although amantadine is considerably less expensive than rimantadine, it crosses the blood-brain barrier and appears to cause more central nervous system side effects, including dizziness, ataxia, hallucinations, agitation, and confusion. This is especially true in elderly patients and may be associated with higher serum concentrations. A split dosage may help minimize adverse events.

Amantadine is primarily eliminated in the kidneys as unchanged drug; therefore, the dosage must be modified in elderly patients and patients with reduced renal function (Table 4).8

TABLE 4
Amantadine (Symmetrel) Dosing Guidelines in Patients with Renal Impairment

Creatinine clearance, mL per minute (mL per second)	Suggested maintenance regimen
30 to 50 (0.5 to 0.83)	100 mg daily*
15 to 29 (0.25 to 0.48)	100 mg every other day*
< 15 (0.25)	200 mg every seven days

*—Loading dose of 200 mg recommended on the first day in patients with creatinine clearance between 50 and 15 mL per minute.

Information from Symmetrel [package insert]. Chadds Ford, Pa.: Endo Pharmaceuticals, 2002.

Rimantadine's adverse drug-reaction profile is similar to that of amantadine with respect to gastrointestinal side effects such as nausea, vomiting, and dyspepsia, but rimantadine appears to cause fewer central nervous system side effects.9

Oseltamivir and Zanamivir

Oseltamivir, which is taken orally, was approved for prophylaxis of influenza in late 2000, and zanamivir's approval for prophylaxis is pending. They are equally effective in reducing symptoms and duration of illness when taken within 48 hours of the onset of symptoms.10–14

Zanamivir is inhaled and requires the use of an inhalation device, which may be difficult for elderly patients to use. Because of its potential to induce bronchospasm and reduce lung function, use of zanamivir generally should be avoided in patients with asthma and chronic obstructive pulmonary disease.

INFLUENZA TYPE B

Oseltamivir and zanamivir are first-line choices for prevention and treatment of infection during outbreaks of influenza type B.

Respiratory Syncytial Virus (RSV)

RSV is a frequent cause of bronchiolitis in children. Treatment consists primarily of supportive care with fluids, oxygen, and aerosolized bronchodilators.

Ribavirin

In a select group of high-risk infants (premature infants younger than 36 weeks and infants with bronchopulmonary dysplasia, congenital heart disease, or immunodeficiency) with severe infections, aerosolized ribavirin (Virazole) has been used.15 The use of this drug requires special equipment and expert respiratory monitoring. It is expensive, with a cost exceeding $1,000 per day.

RSV Immune Globulin and Palivizumab

In high-risk patients, prophylaxis against RSV should be considered. During the winter months, monthly administration of intravenous RSV immune globulin (RespiGam) or intramuscular palivizumab (Synagis) may decrease the number of RSV episodes. Because of increased morbidity, RSV immune globulin should not be given to patients with congenital heart disease.

The authors thank David Oldach, M.D., for review of the manuscript.

The authors indicate that they do not have any conflicts of interest. Sources of funding: none reported.

REFERENCES

1. Physicians' desk reference. Accessed November 2002 at: www.pdr.net (with password).

2. �Drugs for non-HIV viral infections.. �Med Lett Drugs Ther. �1999;41:113–20.

3. �Influenza prevention 2002–2003.. �Med Lett Drugs Ther. �2002;44:75–6.

4. �Influenza prevention 2001–2002.. �Med Lett Drugs Ther. �2001;43:81–2.

5. Van Voris �LP, Betts �RF, Hayden �FG, Christmas �WA, Douglas �RG �Jr. �Successful treatment of naturally occurring influenza A/USSR/77 H1N1. �JAMA. �1981;245:1128–31.

6. Couch �RB. �Prevention and treatment of influenza. �N Engl J Med. �2000;343:1778–87.

7. Demicheli �V, Jefferson �T, Rivetta �D, Deeks �J. �Prevention and early treatment of influenza in healthy adults. �Vaccine. �2000;18:957–1030.

8. Symmetrel [package insert]. Chadds Ford, Pa.: Endo Pharmaceuticals, 2002.

9. Dolin �R, Reichman �RC, Madore �HP, Maynard �L, Linton �PN, Webber-Jones �J. �A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. �N Engl J Med. �1982;307:580–4.

10. Lalezari �J, Campion �K, Keene �O, Silagy �C. �Zanamivir for the treatment of influenza A and B infection in high-risk patients: a pooled analysis of randomized controlled trials. �Arch Intern Med. �2001;161:212–7.

11. McClellan �K, Perry �CM. �Oseltamivir: a review of its use in influenza. �Drugs. �2001;61:263–83.

12. Monto �AS, Moult �AB, Sharp �SJ. �Effect of zanamivir on duration and resolution of influenza symptoms. �Clin Ther. �2000;22:1294–305.

13. Whitley �RJ, Hayden �FG, Reisinger �KS, Young �N, Dutkowski �R, Ipe �D, et al. �Oral oseltamivir treatment of influenza in children. �Pediatr Infect Dis J. �2001;20:127–33.

14. Montalto �NJ, Gum �KD, Ashley �JV. �Updated treatment for influenza A and B. �Am Fam Physician. �2000;62:2467–76.

15. �Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn. �Pediatrics. �1998;102:1211–6.

Richard W. Sloan, M.D., R.PH., coordinator of this series, is chairman of the Department of Family Medicine at York (Pa.) Hospital and clinical associate professor in family and community medicine at the Milton S. Hershey Medical Center, Pennsylvania State University, Hershey, Pa.

Copyright � 2003 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.